Cooper Companies' $51 mil. Aspect buy would add European distribution arm.
This article was originally published in The Gray Sheet
Executive Summary
COOPER COMPANIES' $51 MIL. ASPECT VISION BUY WOULD ADD EUROPEAN DISTRIBUTION platform for the CooperVision contact lens business, according to a definitive agreement announced Nov. 20. The definitive pact follows a Sept. 3 non-binding letter of intent ("The Gray Sheet" Sept. 8, In Brief). Southampton, England-based spherical contact lens maker Aspect Vision Care "is an ideal platform to launch our specialty lens product line into the European market," Cooper CEO and CooperVision president Thomas Bender states.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.